Johnson & Johnson Jumps on Pharma Strength
Johnson & Johnson (NYSE: JNJ) has been a behemoth in the U.S. healthcare space for decades. Yet as a mature company, J&J faces the inevitable challenge of finding ways to keep its growth rates up even as its business gets ever larger. Results from recent quarters had shown signs of potentially slowing increases in sales and profits, and that raised some worries among longtime investors that Johnson & Johnson might have hit peak growth in its core business.
Coming into Tuesday's third-quarter financial report, Johnson & Johnson shareholders wanted reassurances that aggressive moves like the acquisition of Actelion would pay off with better fundamental performance. J&J's report strongly suggested that its long-term strategy is working well, and the company seems more optimistic than ever that its combination of organic growth opportunities and smart acquisitions can help power it forward in the years to come.
Image source: Johnson & Johnson.
Source: Fool.com
Johnson & Johnson Stock
With 57 Buy predictions and not a single Sell prediction Johnson & Johnson is an absolute favorite of our community.
As a result the target price of 228 € shows a slightly positive potential of 1.11% compared to the current price of 225.5 € for Johnson & Johnson.
